{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ejo M"],"funding":["Medical Research Council"],"pagination":["839-845"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7614701"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(10)"],"pubmed_abstract":["<b>OBJECTIVES:</b> To assess the performance of the GenoType MTBDR<i>sl</i> v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial.<b>METHODS:</b> Direct sputum MTBDR<i>sl</i> results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard.<b>RESULTS:</b> Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDR<i>sl</i> and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDR<i>sl</i> result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) "],"journal":["The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease"],"pubmed_title":["Effectiveness of GenoType MTBDR&lt;i&gt;sl&lt;/i&gt; in excluding TB drug resistance in a clinical trial."],"pmcid":["PMC7614701"],"funding_grant_id":["MC_EX_MR/J012513/1","MC_UU_00004/04","MR/J012513/1","MC_UU_12023/26"],"pubmed_authors":["Diro E","Meredith S","Ahmed S","Ejo M","Kokebu D","Keysers J","Tumenbayar O","Duckworth L","Ngubane N","Conradie F","Mulders W","De Rijk P","Hang PT","Enduwamahoro E","Dat PT","Mebrahtu T","Moodliar R","Van Deun A","Tsogt B","Torrea G","de Jong BC","Ha DTM","Nunn A","Dalai D","Rigouts L","Teferi M"],"additional_accession":[]},"is_claimable":false,"name":"Effectiveness of GenoType MTBDR&lt;i&gt;sl&lt;/i&gt; in excluding TB drug resistance in a clinical trial.","description":"<b>OBJECTIVES:</b> To assess the performance of the GenoType MTBDR<i>sl</i> v1, a line-probe assay (LPA), to exclude baseline resistance to fluoroquinolones (FQs) and second-line injectables (SLIs) in the Standard Treatment Regimen of Anti-tuberculosis Drugs for Patients With MDR-TB 1 (STREAM 1) trial.<b>METHODS:</b> Direct sputum MTBDR<i>sl</i> results in the site laboratories were compared to indirect phenotypic drug susceptibility testing (pDST) results in the central laboratory, with DNA sequencing as a reference standard.<b>RESULTS:</b> Of 413 multidrug-resistant TB (MDR-TB) patients tested using MTBDR<i>sl</i> and pDST, 389 (94.2%) were FQ-susceptible and 7 (1.7%) FQ-resistant, while 17 (4.1%) had an inconclusive MTBDR<i>sl</i> result. For SLI, 372 (90.1%) were susceptible, 5 (1.2%) ","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Oct","modification":"2026-05-29T06:02:57.998Z","creation":"2024-11-05T20:26:02.788Z"},"accession":"S-EPMC7614701","cross_references":{"pubmed":["34615581"],"doi":["10.5588/ijtld.21.0212"]}}